US FDA Approves Labcorp’s Companion Diagnostic Test for Advanced Melanoma: Here’s What To Know

The US Food and Drug Administration (FDA) has approved Labcorp’s PGDx elio tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapies.

PGDx elio tissue complete CDx helps clinicians identify which melanoma patients carry BRAF V600E/K variants and may benefit from treatment with FDA-approved BRAF inhibitors and BRAF/MEK inhibitor combination regimens. PGDx elio tissue complete CDx is a qualitative next generation sequencing-based in vitro diagnostic device that uses a high-throughput hybridization-based capture technology utilizing DNA isolated from formalin-fixed paraffin embedded tumor tissue. The PGDx elio tissue complete CDx targeted panel can detect single nucleotide variants, small insertions and deletions, copy number amplifications, and translocations.

PGDx elio tissue complete CDx Indications
Indication: Melanoma
Biomarker: BRAF V600E/ BRAF V600K
Therapy: BRAF inhibitors approved by FDA or BRAF/MEK inhibitor combinations approved by FDA

“Advanced melanoma is an extremely aggressive and life‑threatening cancer, but targeted treatments are offering real hope for patients,” says Shakti Ramkissoon, MD, PhD, Vice President, Medical Lead for Oncology at Labcorp, in a news release. “Labcorp’s FDA‑approved companion diagnostic improves access to these therapies by allowing clinicians to confirm which patients may be eligible for and can start receiving those treatments as soon as possible.”

Labcorp’s PGDx elio tissue complete CDx is approved for use by qualified healthcare professionals across hospitals and clinical laboratories. As a kit-based solution, the companion diagnostic can be implemented directly within hospitals and health systems.